Is acotinib/acalabrutinib covered by medical insurance?

Acalabrutinib/Acalabrutinib, as an important original drug, can be used to treat adult patients with mantle cell lymphoma who have received at least one treatment for this disease; it can also be used to treat adult chronic lymphocytic leukemia or small lymphocytic lymphoma. Acotinib may also be used for purposes not listed in this Medication Guide. Acotinib has been officially launched in China, providing a new treatment option for patients. The development and launch of this drug has undoubtedly injected new vitality into the medical community and brought hope to those patients who are suffering from the disease.

The launch of acotinib not only means the improvement of domestic pharmaceutical standards, but also reflects the country’s emphasis on and investment in medical care. What is even more worth mentioning is that acotinib has been included in the medical insurance system, which has greatly reduced the financial burden on patients and enabled more patients to have access to this highly effective drug. However, it should be noted that medical insurance reimbursement for acotinib is not available to all patients. According to regulations, only adult patients with mantle cell lymphoma (MCL) who have received at least one type of treatment in the past can enjoy medical insurance reimbursement. This regulation aims to ensure that drugs can be accurately used for patients who need them most, and also reflects the reasonable allocation of medical insurance resources.

In terms of drug specifications, the common specifications of acotinib are 100*mg, 8 tablets and 7 plates. However, the price of each box is as high as more than 40,000 yuan, which is undoubtedly a huge expense for many families. Therefore, medical insurance reimbursement is particularly important. However, it should be noted that due to differences in reimbursement ratios in different regions, the price for patients after using medical insurance reimbursement may be different. In order to obtain the most accurate information, patients are advised to consult the local medical insurance bureau or hospital and other relevant departments.